Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other financing activities (2021 - 2024)

Historic Other financing activities for Vivos Therapeutics (VVOS) over the last 3 years, with Q4 2024 value amounting to $446000.0.

  • Vivos Therapeutics' Other financing activities rose 324.07% to $446000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 2167.78%. This contributed to the annual value of $1.4 million for FY2024, which is 2636.95% up from last year.
  • Latest data reveals that Vivos Therapeutics reported Other financing activities of $446000.0 as of Q4 2024, which was up 324.07% from $509000.0 recorded in Q3 2024.
  • In the past 5 years, Vivos Therapeutics' Other financing activities registered a high of $645000.0 during Q1 2023, and its lowest value of $4000.0 during Q3 2021.
  • Over the past 3 years, Vivos Therapeutics' median Other financing activities value was $432000.0 (recorded in 2023), while the average stood at $348857.1.
  • The largest annual percentage gain for Vivos Therapeutics' Other financing activities in the last 5 years was 324.07% (2024), contrasted with its biggest fall of 5255.81% (2024).
  • Quarter analysis of 3 years shows Vivos Therapeutics' Other financing activities stood at $4000.0 in 2021, then soared by 10700.0% to $432000.0 in 2023, then grew by 3.24% to $446000.0 in 2024.
  • Its Other financing activities stands at $446000.0 for Q4 2024, versus $509000.0 for Q3 2024 and $100000.0 for Q2 2024.